deltatrials
Completed PHASE1 INTERVENTIONAL 5-arm NCT04454424

Study on the Safety of BAY1817080, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug in Participants With Impaired Liver Function or Normal Liver Function

An Open-label Study to Evaluate the Pharmacokinetics, Safety and Tolerability of BAY 1817080 in Participants With Impaired Hepatic Function (Classified as Child-Pugh A, B or C) in Comparison to Matched Controls With Normal Hepatic Function

Sponsor: Bayer

Conditions Diabetic Neuropathic Pain Endometriosis Related Pain Overactive Bladder Refractory or Unexplained Chronic Cough
Interventions BAY1817080 Midazolam
Updated 18 times since 2020 Last updated: Jan 19, 2023 Started: Jul 23, 2020 Primary completion: Jun 24, 2021 Completion: Dec 15, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Diabetic Neuropathic Pain and Endometriosis Related Pain and is currently completed. Bayer leads this study, which shows 18 recorded versions since 2020 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Aug 2020 – ~Sep 2020 · 31 days · monthly snapshot~Sep 2020 – ~Oct 2020 · 30 days · monthly snapshot~Oct 2020 – ~Dec 2020 · 2 months · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Mar 2021 · 28 days · monthly snapshot~Mar 2021 – ~Apr 2021 · 31 days · monthly snapshot~Apr 2021 – ~May 2021 · 30 days · monthly snapshot~May 2021 – ~Jun 2021 · 31 days · monthly snapshot~Jun 2021 – ~Sep 2021 · 3 months · monthly snapshot~Sep 2021 – ~Oct 2021 · 30 days · monthly snapshot~Oct 2021 – ~Dec 2021 · 2 months · monthly snapshot~Dec 2021 – ~Jan 2022 · 31 days · monthly snapshot~Jan 2022 – ~Feb 2022 · 31 days · monthly snapshot~Feb 2022 – ~Feb 2023 · 12 months · monthly snapshot~Feb 2023 – ~Jul 2024 · 17 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

18 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  3. Feb 2023 — Jul 2024 [monthly]

    Completed PHASE1

  4. Feb 2022 — Feb 2023 [monthly]

    Completed PHASE1

    Status: Active Not Recruiting → Completed

  5. Jan 2022 — Feb 2022 [monthly]

    Active Not Recruiting PHASE1

▶ Show 13 earlier versions

  1. Dec 2021 — Jan 2022 [monthly]

    Active Not Recruiting PHASE1

  2. Oct 2021 — Dec 2021 [monthly]

    Active Not Recruiting PHASE1

  3. Sep 2021 — Oct 2021 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  4. Jun 2021 — Sep 2021 [monthly]

    Recruiting PHASE1

  5. May 2021 — Jun 2021 [monthly]

    Recruiting PHASE1

  6. Apr 2021 — May 2021 [monthly]

    Recruiting PHASE1

  7. Mar 2021 — Apr 2021 [monthly]

    Recruiting PHASE1

  8. Feb 2021 — Mar 2021 [monthly]

    Recruiting PHASE1

  9. Jan 2021 — Feb 2021 [monthly]

    Recruiting PHASE1

  10. Dec 2020 — Jan 2021 [monthly]

    Recruiting PHASE1

  11. Oct 2020 — Dec 2020 [monthly]

    Recruiting PHASE1

  12. Sep 2020 — Oct 2020 [monthly]

    Recruiting PHASE1

  13. Aug 2020 — Sep 2020 [monthly]

    Recruiting PHASE1

    First recorded

Jul 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Bayer
Data source: Bayer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations